Ann‐Lii Cheng

75.6k total citations · 11 hit papers
794 papers, 28.2k citations indexed

About

Ann‐Lii Cheng is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ann‐Lii Cheng has authored 794 papers receiving a total of 28.2k indexed citations (citations by other indexed papers that have themselves been cited), including 412 papers in Oncology, 285 papers in Hepatology and 229 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ann‐Lii Cheng's work include Hepatocellular Carcinoma Treatment and Prognosis (271 papers), Colorectal Cancer Treatments and Studies (125 papers) and Lung Cancer Treatments and Mutations (84 papers). Ann‐Lii Cheng is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (271 papers), Colorectal Cancer Treatments and Studies (125 papers) and Lung Cancer Treatments and Mutations (84 papers). Ann‐Lii Cheng collaborates with scholars based in Taiwan, United States and Japan. Ann‐Lii Cheng's co-authors include Chih‐Hung Hsu, Chiun Hsu, Masatoshi Kudo, Kun‐Huei Yeh, Pei‐Jer Chen, Shuang‐En Chuang, Ying‐Chun Shen, Liang‐In Lin, Jen‐Kun Lin and Yu‐Yun Shao and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Ann‐Lii Cheng

777 papers receiving 27.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Stability of curcumin in buffer solutions and characterization of its degradation products

1997 1.4k citations Ann‐Lii Cheng, Liang‐In Lin et al. profile →
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

2019 1.3k citations Richard S. Finn, Baek‐Yeol Ryoo et al. Journal of Clinical Oncology profile →
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

2021 891 citations Ann‐Lii Cheng, Ho Yeong Lim et al. profile →
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

2013 586 citations Ann‐Lii Cheng, Joong‐Won Park et al. Journal of Clinical Oncology profile →
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

2019 497 citations Thomas Yau, Richard S. Finn et al. Annals of Oncology profile →
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies

2017 421 citations Ann‐Lii Cheng et al. profile →
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

2020 386 citations Ann‐Lii Cheng, Chiun Hsu et al. profile →
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

2020 274 citations Richard S. Finn, Ghassan K. Abou‐Alfa et al. profile →
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

2021 229 citations Richard S. Finn, Ho Yeong Lim et al. Journal of Clinical Oncology profile →
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

2020 194 citations Masatoshi Kudo, Stephen L. Chan et al. profile →
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

2022 135 citations Masatoshi Kudo, Philippe Merle et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Ann‐Lii Cheng

Since Specialization

Citations

This map shows the geographic impact of Ann‐Lii Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann‐Lii Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann‐Lii Cheng more than expected).

Fields of papers citing papers by Ann‐Lii Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann‐Lii Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann‐Lii Cheng. The network helps show where Ann‐Lii Cheng may publish in the future.

Co-authorship network of co-authors of Ann‐Lii Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Ann‐Lii Cheng. A scholar is included among the top collaborators of Ann‐Lii Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann‐Lii Cheng. Ann‐Lii Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cyclin dependent kinase 9 inhibition reduced programmed death-ligand 1 expression and improved treatment efficacy in hepatocellular carcinoma 2024 ·Heliyon ·Yu‐Yun Shao, Min‐Shu Hsieh, Yi‐Hsuan Lee, (unknown), (unknown), Hanyu Wang, Ann‐Lii Cheng, Chih‐Hung Hsu	1
2	Cooperative participation of CagA and NFATc1 in the pathogenesis of antibiotics-responsive gastric MALT lymphoma 2024 ·Cancer Cell International ·Hui‐Jen Tsai, Kun‐Huei Yeh, Chung‐Wu Lin, Ming-Shiang Wu, Jyh‐Ming Liou, Ping‐Ning Hsu, (unknown), (unknown), Chia‐Tung Shun, Hsiu-Po Wang, (unknown), Ann‐Lii Cheng, Sung‐Hsin Kuo	0
3	LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC) 2024 ·Annals of Oncology ·Adam C. Yopp, (unknown), Mingkai Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, (unknown), Songbing Qin, Edward Cha, Stephen P. Hack, Qinshu Lian, (unknown), (unknown), Pierce K. H. Chow	35
4	Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma 2023 ·Cancer Letters ·Zhong‐Zhe Lin, Mickey C.‐T. Hu, Chiun Hsu, Yao‐Ming Wu, Yen‐Shen Lu, Ja‐an Annie Ho, Shiou‐Hwei Yeh, Pei‐Jer Chen, Ann‐Lii Cheng	7
5	Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity 2023 ·Journal of Clinical and Translational Hepatology ·Chiao‐Ling Tsai, (unknown), Feng‐Ming Hsu, Ann‐Lii Cheng, (unknown), Jason Chia‐Hsien Cheng	3
6	A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma 2022 ·Clinical Cancer Research ·Tom Wei‐Wu Chen, Chia‐Lang Hsu, Ruey‐Long Hong, Jen‐Chieh Lee, Koping Chang, Chih‐Wei Yu, San‐Chi Chen, (unknown), (unknown), (unknown), (unknown), Ann‐Lii Cheng, Chueh‐Chuan Yen	9
7	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma 2020 ·Clinical Cancer Research ·Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Philippe Merle, Joong‐Won Park, Thomas Yau, Stephen L. Chan, Jean‐Frédéric Blanc, Vincent C. Tam, Albert Tran, Vincenzo Dadduzio, David W. Markby, Rajesh Kaldate, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	66
8	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial breakdown → 2019 ·Journal of Clinical Oncology ·Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, (unknown)	1300
9	Quality-adjusted life-years accrued with cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial 2019 ·UCL Discovery (University College London) ·Simone I. Strasser, Ghassan K. Abou‐Alfa, Patrick Mollon, T Meyer, Ann‐Lii Cheng, (unknown), (unknown), (unknown), Fawzi Benzaghou, (unknown), Saswati Hazra, Milan Mangeshkar, Nick Freemantle	0
10	Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC) 2018 ·Annals of Oncology ·Thomas Yau, Philippe Merle, Lorenza Rimassa, Baek‐Yeol Ryoo, (unknown), William Proctor Harris, Eugéniu Banu, Debashis Sarker, Benjamin Tan, Hans Van Vlierberghe, Seema Sen, (unknown), Ann‐Lii Cheng, T Meyer, Robin Kate Kelley, Ghassan K. Abou‐Alfa	4
11	Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression 2015 ·Clinical Cancer Research ·Chiun Hsu, Liang‐In Lin, Yu‐Che Cheng, (unknown), Yu‐Yun Shao, Ann‐Lii Cheng, Da‐Liang Ou	40
12	Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy 2015 ·Clinical Cancer Research ·Yen‐Shen Lu, Tom Wei‐Wu Chen, Ching‐Hung Lin, Dah‐Cherng Yeh, Ling‐Ming Tseng, Pei‐Fang Wu, Kun‐Ming Rau, Bang‐Bin Chen, Ta‐Chung Chao, Shu‐Min Huang, Chiun‐Sheng Huang, Tiffany Ting‐Fang Shih, Ann‐Lii Cheng	71
13	Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas 2012 ·Blood ·Sung‐Hsin Kuo, Kun‐Huei Yeh, Ming‐Shiang Wu, Chung‐Wu Lin, Ping‐Ning Hsu, Hsiu-Po Wang, Li‐Tzong Chen, Ann‐Lii Cheng	95
14	Translocation of Helicobacter pylori CagA into Human B Lymphocytes, the Origin of Mucosa-Associated Lymphoid Tissue Lymphoma 2010 ·Cancer Research ·(unknown), Hwei-Fang Tsai, Sung‐Hsin Kuo, Ming‐Shiang Wu, Chung‐Wu Lin, Ping-I Hsu, Ann‐Lii Cheng, Ping‐Ning Hsu	80
15	Induction of DNA Damage-Inducible Gene GADD45β Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells 2010 ·Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Sung‐Liang Yu, Kuen‐Feng Chen, (unknown), (unknown), Wen-Chi Feng, (unknown), Liang‐In Lin, Chiun Hsu, Ann‐Lii Cheng	68
16	Induction of Bim Expression Contributes to the Antitumor Synergy Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular Carcinoma 2009 ·Clinical Cancer Research ·Da‐Liang Ou, Ying‐Chun Shen, Ja‐Der Liang, Jun‐Yang Liou, Sung‐Liang Yu, (unknown), Dasheng Wang, Yen‐Shen Lu, Chiun Hsu, Ann‐Lii Cheng	36
17	Breast Cancer–Associated Fibroblasts Confer AKT1-Mediated Epigenetic Silencing of Cystatin M in Epithelial Cells 2008 ·Cancer Research ·Huey‐Jen Lin, Tao Zuo, Ching‐Hung Lin, (unknown), Sandya Liyanarachchi, Shuying Sun, Rulong Shen, Daniel E. Deatherage, (unknown), (unknown), Shili Lin, Pearlly S. Yan, Ann‐Lii Cheng, Michael C. Ostrowski, Tim H-M. Huang	55
18	Sulfasalazine Suppresses Drug Resistance and Invasiveness of Lung Adenocarcinoma Cells Expressing AXL 2007 ·Cancer Research ·(unknown), Chih-Chen Hong, (unknown), (unknown), (unknown), (unknown), (unknown), Gi‐Ming Lai, Ann‐Lii Cheng, Ih‐Jen Su, Shuang‐En Chuang	90
19	Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma 1996 ·Cancer ·Ann‐Lii Cheng, Yee‐Chun Chen, Kun‐Huei Yeh, Shuang‐En Chuang, (unknown), Ding‐Shinn Chen	1
20	Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki‐1 anaplastic large cell lymphoma: Special emphasis on the tumor response to 13‐Cis retinoic acid 1996 ·Cancer ·Wen‐Chien Chou, Ih‐Jen Su, Hwei‐Fang Tien, Der‐Cherng Liang, Chiu‐Hwa Wang, (unknown), Ann‐Lii Cheng	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact